Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from ZYUS Life Sciences ( (TSE:ZYUS) ).
Brent H. Zettl, President and CEO of ZYUS Life Sciences Corporation, has updated his holdings in the company following an agreement to amend a secured promissory note. This amendment involves issuing 4,347,826 bonus warrants to 102042227 Saskatchewan Ltd, a company owned by Zettl, subject to TSXV approval. This transaction will increase Zettl’s control over ZYUS’s common shares from 44.0% to 46.9% on a partially diluted basis, reflecting a strategic move for investment purposes. The issuance of these warrants is expected to enhance ZYUS’s market positioning and could influence future investment and operational strategies.
The most recent analyst rating on (TSE:ZYUS) stock is a Buy with a C$1.50 price target. To see the full list of analyst forecasts on ZYUS Life Sciences stock, see the TSE:ZYUS Stock Forecast page.
More about ZYUS Life Sciences
ZYUS Life Sciences Corporation operates in the life sciences industry, focusing on the development and commercialization of cannabinoid-based therapeutics. The company aims to leverage the therapeutic potential of cannabinoids to address unmet medical needs, positioning itself as a leader in this niche market.
Average Trading Volume: 11,213
Technical Sentiment Signal: Sell
Current Market Cap: C$46.67M
Learn more about ZYUS stock on TipRanks’ Stock Analysis page.